|

Trastuzumab (or biosimilar) Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Shanghai Jiao Tong University School of Medicine1
  • Fudan University1

Indications

  • Breast Cancer2
  • Cancer2
  • HER2 + Breast Cancer1
  • Metastatic Breast Cancer1
  • Triple Negative Breast Cancer (TNBC)1

Other2 trials

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.